, Tracking Stock Market Picks
Enter Symbol:
Galectin Therapeutics Inc (GALT) [hlAlert]

down 73.39 %

Galectin Therapeutics Inc (GALT) rated Buy with price target $10 by Aegis Capital

Posted on: Monday,  Aug 19, 2013  9:25 AM ET by Aegis Capital

Aegis Capital rated Buy Galectin Therapeutics Inc (NASDAQ: GALT) on 08/19/2013, when the stock price was $6.99. Since
then, Galectin Therapeutics Inc has lost 73.39% as of 09/21/2015's recent price of $1.86.
If you would have followed this Aegis Capital's recommendation on GALT, you would have lost 73.39% of your investment in 763 days.

Pro-Pharmaceuticals, Inc. is a development-stage company engaged in the discovery and development of Galectin-targeting therapeutics. The Company focuses on the development of anti-cancer treatments using polysaccharide polymers. As of December 31, 2009, the Company?s products were in development, including pre-clinical and clinical trials. As of December 31, 2009, the Company was developing a pipeline of compounds that may be combined with chemotherapies, such as 5-FU and biologics, such as Avastin. As of December 31, 2009, DAVANAT had been administered to approximately 100 cancer patients in Phase I and II trials. As of December 31, 2009, the Company was developing other therapeutic compounds for treatment of other serious disease, such as liver and kidney fibrosis. These product candidates are all in the pre-clinical stage of development.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/10/2014 10:25 AM Buy
15.57 32.00
as of 12/13/2013
1 Week down  -10.88 %
1 Month up  7.40 %
3 Months down  -16.88 %
1 YTD up  18.31 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/9/2014 2:25 PM Buy
11.12 16.00
8/19/2013 9:25 AM Buy
6.99 10.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy